Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726333 · ClinicalTrials.gov registry record · Phase 1
Hepatic Impairment Study for Lorlatinib in Cancer Patients
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03726333 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT03726333, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
Interventions
- DRUG lorlatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726333
The ClinicalTrials.gov registry entry for NCT03726333 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lorlatinib is the first listed.
NCT03726333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03726333 about?
NCT03726333 is a clinical study titled "Hepatic Impairment Study for Lorlatinib in Cancer Patients". This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
What is the current status of trial NCT03726333?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-01-14. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT03726333?
The interventions under investigation include: lorlatinib (DRUG).
Who is sponsoring clinical trial NCT03726333?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.